Tyrosine Kinase/Adaptors
Tyrosine kinase and adaptor inhibitors are compounds that target tyrosine kinases and their associated adaptor proteins, which play pivotal roles in cell signaling, growth, and differentiation. These inhibitors are essential tools in cancer research, as many tyrosine kinases are involved in the signaling pathways that drive tumor growth and metastasis. By inhibiting tyrosine kinases, these compounds can block critical signaling cascades, offering potential therapeutic strategies for various cancers and other diseases involving abnormal cell signaling. At CymitQuimica, we provide a comprehensive range of high-quality tyrosine kinase and adaptor inhibitors to support your research in oncology, molecular biology, and targeted therapy development.
Subcategories of "Tyrosine Kinase/Adaptors"
- ALK(132 products)
- CSF-1R(42 products)
- EGFR(591 products)
- Ephrin Receptor(25 products)
- FLT(91 products)
- Fibroblast Growth Factor Receptor (FGFR)(182 products)
- HER(3 products)
- Hck(3 products)
- IGF-1R(104 products)
- PDGFR(128 products)
- PYK2(7 products)
- Src(82 products)
- TAM Receptor(33 products)
- Tie-2(20 products)
- Trk receptor(58 products)
- Tyrosine Kinases(25 products)
- VEGFR(246 products)
- c-Fms(112 products)
- c-Kit(115 products)
- c-Met/HGFR(139 products)
- c-RET(61 products)
Show 13 more subcategories
Found 1153 products of "Tyrosine Kinase/Adaptors"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-30
CAS:EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.Formula:C28H33BrN7O2PColor and Shape:SolidMolecular weight:610.49HER2-IN-5
CAS:HER2-IN-5 is an effective inhibitor of orally active HER-2.Formula:C27H33N7O3Color and Shape:SolidMolecular weight:503.6Nazartinib S-enantiomer
CAS:Nazartinib is an EGFR inhibitor. Nazartinib S-enantiomer is the less active S-enantiomer of Nazartinib.Formula:C26H31ClN6O2Purity:98%Color and Shape:SolidMolecular weight:495.02MS 154
CAS:MS 154 is a potent PROTAC® targeting mutant EGFR in lung cancer, sparing WT-EGFR; effective in mice, with DC50 of 11-25 nM.Formula:C46H54ClFN8O8Color and Shape:SolidMolecular weight:901.42TL02-59
CAS:TL02-59: Fgr inhibitor (IC50=0.03nM), also targets Lyn (0.1nM), Hck (160nM), halts acute myelogenous leukemia growth.Formula:C32H34F3N5O4Purity:98.77%Color and Shape:SolidMolecular weight:609.64Ref: TM-T13186
1mg49.00€2mg62.00€5mg93.00€10mg133.00€25mg260.00€50mg401.00€100mg557.00€200mg790.00€1mL*10mM (DMSO)111.00€FGFR3-IN-6
CAS:FGFR3-IN-6 is a potent, selective inhibitor of FGFR 3, exhibiting an IC50 value of less than 350 nM , and is utilized in cancer research [1].Formula:C25H23FN8O2Purity:98%Color and Shape:SolidMolecular weight:486.5c-Fms-IN-14
CAS:c-Fms-IN-14 (Example 76) is a potent inhibitor of the c-Fms kinase with an IC50 of 4 nM, utilized in cancer and autoimmune disease research [1].Formula:C26H24N6OPurity:98%Color and Shape:SolidMolecular weight:436.51EGFR-IN-32
CAS:EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)Formula:C31H34N6O3Color and Shape:SolidMolecular weight:538.64AXL-IN-15
CAS:AXL-IN-15 (cpd391) is a potent inhibitor of Axl, exhibiting both a dissociation constant (K i) and a half-maximal inhibitory concentration (IC50) of less than 1Formula:C26H32F3N9O3Purity:98%Color and Shape:SolidMolecular weight:575.59UniPR1447
CAS:UniPR1447 is a dual antagonist for both EphA2 and EphB2 receptors, exhibiting an IC50 value of 6.6 μM against EphA2-ephrin-A1 binding [1].Formula:C36H50N2O4Purity:98%Color and Shape:SolidMolecular weight:574.79EGFR/HER2-IN-13
CAS:EGFR/HER2-IN-13 (Compd 38) serves as an inhibitor targeting mutant EGFR/HER2s that show resistance to existing drugs. It is primarily utilized in cancer research.Formula:C27H36N8O3Molecular weight:520.63Rocbrutinib
CAS:Rocbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits antineoplastic properties [1].Formula:C42H51N9O5Color and Shape:SolidMolecular weight:761.91UniPR505
CAS:<p>UniPR505 is a potent EphA2 antagonist (IC50: 0.95 µM), a novel 3α-carbamoyloxy derivative with antiangiogenic properties.</p>Formula:C39H57N3O5Purity:98.23%Color and Shape:SolidMolecular weight:647.89FGFR4-IN-16
CAS:FGFR4-IN-16 (CY-15-2) is a covalent inhibitor targeting FGFR-4, utilized in cancer research [1].Formula:C35H30Cl2N6O5Purity:98%Color and Shape:SolidMolecular weight:685.56EGFR/HER2-IN-11
CAS:EGFR/HER2-IN-11 (compound 20), an orally active dual inhibitor targeting human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), demonstrates IC50 values of 7.7 nM and 22 nM, respectively. This compound shows strong antitumor efficacy, specifically inhibiting the proliferation of BT-474 cancer cells with a GI50 of 601 nM [1].Formula:C23H21ClF3N5O2Molecular weight:491.89TRK-IN-24
CAS:TRK-IN-24 (compound 10g) is a selective inhibitor of Trk receptors, effectively targeting TRKA, TRKC, and mutant forms TRKA G595R, TRKA G667C, and TRKA F589L,Formula:C39H45N7O3Purity:98%Color and Shape:SolidMolecular weight:659.82EGFR-IN-33
CAS:EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).Formula:C26H25ClN6O2Color and Shape:SolidMolecular weight:488.97Zidesamtinib
CAS:Zidesamtinib (NVL-520) is a ROS1 fusion and resistance mutation inhibitor that inhibits ROS1 and can be used to study non-small cell lung cancer.Formula:C22H22FN7OPurity:99.74%Color and Shape:SolidMolecular weight:419.455Ref: TM-T72953
1mg74.00€5mg160.00€10mg250.00€25mg507.00€50mg810.00€100mg1,293.00€200mg1,738.00€1mL*10mM (DMSO)170.00€CH6953755
CAS:CH6953755: oral YES1 kinase inhibitor, IC50 1.8 nM, potent, selective, anticancer, halts cell proliferation.Formula:C26H22F2N6O4SPurity:98.87%Color and Shape:SolidMolecular weight:552.55Ref: TM-T10784
1mg58.00€5mg123.00€10mg187.00€25mg366.00€50mg588.00€100mg944.00€1mL*10mM (DMSO)149.00€EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purity:98.64%Color and Shape:SolidMolecular weight:499.61EGFR-IN-1 hydrochloride
CAS:EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.Formula:C28H31ClN6O4Purity:99.16%Color and Shape:SolidMolecular weight:551.04Ref: TM-T11157L
1mg62.00€5mg142.00€10mg205.00€25mg319.00€50mg429.00€100mg587.00€200mg795.00€1mL*10mM (DMSO)190.00€BTK inhibitor 1
CAS:<p>BTK inhibitor 1 (Compound 27) is a BTK inhibitor (IC50: 0.11 nM) with an inhibitory effect on B-cell activation in hWB with an IC50 of 2 nM.</p>Formula:C24H23FN8O2Purity:98.24% - 98.91%Color and Shape:SolidMolecular weight:474.49MK-2461
CAS:MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with anFormula:C24H25N5O5SPurity:95.41% - 99.67%Color and Shape:SolidMolecular weight:495.55Ref: TM-T6094
1mg52.00€5mg120.00€10mg187.00€25mg363.00€50mg552.00€100mg842.00€200mg1,130.00€1mL*10mM (DMSO)134.00€FIIN-1
CAS:FIIN-1 (FGFR irreversible inhibitor-1) is an irreversible and selective FGFR inhibitor with Kd of 2.8, 6.9, 5.4, 120, 32 and 120 nM for FGFR1, FGFR2, FGFR3,Formula:C32H39Cl2N7O4Purity:98.75%Color and Shape:SolidMolecular weight:656.6Ref: TM-T37426
1mg79.00€2mg103.00€5mg202.00€10mg329.00€25mg550.00€50mg783.00€100mg1,035.00€500mg2,118.00€Tyrphostin AG 538
CAS:Tyrphostin AG 538 is a chalcone compound, an IGF-1 receptor kinase inhibitor (IC₅0 : for 400 nM) that is potent, cell-permeable, reversible, and competitive.Formula:C16H11NO5Purity:98.75%Color and Shape:SoildMolecular weight:297.26Sevabertinib
CAS:Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Formula:C24H25ClN4O5Purity:99.81%Color and Shape:SolidMolecular weight:484.93BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Formula:C24H31N5O4Purity:96.74%Color and Shape:SolidMolecular weight:453.53EGFR/ErbB-2 inhibitor-1
CAS:EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.Formula:C23H15ClFN3OS2Purity:98.93%Color and Shape:SolidMolecular weight:467.97Ropsacitinib
CAS:Ropsacitinib (PF-06826647) is a selective TYK2 inhibitor, which binds to TYK2 catalytically active JH1 domain (IC50: 17 nM).Formula:C20H17N9Purity:99.87%Color and Shape:SolidMolecular weight:383.41AZ-23
CAS:AZ-23 is an inhibitor of ATP-competitive and Trk kinase A/B/C.Formula:C17H19ClFN7OPurity:99.4%Color and Shape:SolidMolecular weight:391.83EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Formula:C32H23ClF3N7O4Purity:99.51%Color and Shape:SolidMolecular weight:662.02Src Inhibitor 3
CAS:Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.Formula:C34H32ClFN8O4Purity:98.35%Color and Shape:SolidMolecular weight:671.12Ref: TM-T13000
1mg92.00€5mg187.00€10mg320.00€25mg507.00€50mg702.00€100mgTo inquire1mL*10mM (DMSO)279.00€EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Color and Shape:SolidEGFR-IN-35
CAS:EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96ONO-7579
CAS:ONO-7579, an orally active TRKA inhibitor, effectively suppresses tumor growth by inhibiting TRKA phosphorylation. In KM12 colorectal cancer cells, it exhibits an EC 50 of 17.6 ng/g, indicating that a concentration of 17.6 ng per gram of tumor tissue reduces the activity of phosphorylated TRKA by 50%. This compound is utilized in cancer research.Formula:C24H18ClF3N6O4SColor and Shape:SolidMolecular weight:578.95Neptinib
CAS:Neptinib (NEP010), a derivative of Afatinib, exhibits enhanced antitumor properties and improved pharmacokinetics when administered orally. It demonstrates a notable suppression of tumor expansion in mouse models of non-small cell lung cancer harboring various EGFR mutations. Furthermore, Neptinib effectively inhibits the EGFR kinase family, exhibiting IC 50 values of 0.24 nM for EGFR wt, 7.25 nM for EGFR L858R/T790M, 0.46 nM for EGFR L858R, and 1.79 nM for EGFR T790M.Formula:C22H23ClFN5O2Color and Shape:SolidMolecular weight:443.90LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Formula:C21H20ClN3O4Color and Shape:SolidMolecular weight:413.854KIN-8741
CAS:KIN-8741 is a highly selective and orally active Type IIb c-Met inhibitor. It exhibits broad-spectrum activity against c-Met kinase mutations. KIN-8741 demonstrates antitumor activity in non-small cell lung cancer models with MET gene amplification and exon 14 deletion. It is applicable in research on c-Met-driven cancers, particularly advanced tumors harboring MET exon 14 skipping mutations and acquired resistance mutations.Formula:C26H23F2N3O6Color and Shape:SolidMolecular weight:511.47EGFR-IN-48
EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.Color and Shape:SolidNMS-P626
CAS:<p>NMS-P626 functions as an inhibitor targeting TRKA, TRKB, and TRKC, exhibiting IC 50 values of 8 nM, 7 nM, and 3 nM respectively. It effectively suppresses KM12 cell growth by inhibiting the phosphorylation of TPM3-TRKA and the subsequent downstream signaling, demonstrating an IC 50 of 19 nM specifically for KM12 cells. This compound is applicable in the study of colorectal cancer.</p>Formula:C28H35F2N7O4SColor and Shape:SolidMolecular weight:603.68CGP062464
CAS:CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.Formula:C18H14N4Color and Shape:SolidMolecular weight:286.331UniPR500
CAS:UniPR500, a derivative of UniPR129, is a competitive antagonist for the EphA2 receptor, with a Ki of 0.78 μM. It reduces the binding of biotinylated Ephrin-A1 to EphA2 in a dose-dependent manner, exhibiting an IC50 value of 1.1 μM.Formula:C36H51N3O4Color and Shape:SolidMolecular weight:589.808EGFR-IN-147
CAS:EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formula:C13H13N5OColor and Shape:SolidMolecular weight:255.275HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Formula:C20H18N4O3SColor and Shape:SolidMolecular weight:394.447Tyrphostin 63
CAS:Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Formula:C10H8N2OColor and Shape:SolidMolecular weight:172.183TrkA-IN-9
CAS:TrkA-IN-9 (VMD-928) is an orally active and selective inhibitor of tropomyosin receptor kinase A (TrkA). It disrupts downstream signaling pathways activated by nerve growth factor (NGF) binding to TrkA, thereby inhibiting cell proliferation and invasion, and promoting cancer cell death. TrkA-IN-9 shows potential for research in various cancers, including prostate cancer, thymic carcinoma, mesothelioma, head and neck squamous cell carcinoma, lung cancer, ovarian cancer, and hepatocellular carcinoma.Formula:C31H32N4O4Color and Shape:SolidMolecular weight:524.61BPI-15086
CAS:BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.Formula:C29H33ClN8O4Color and Shape:SolidMolecular weight:593.08FMP-API-1
CAS:FMP-API-1 is an inhibitor of the A-kinase anchoring protein (AKAP)-PKA interaction. It binds to the allosteric site of the PKAR subunit, enhancing the activity of PKA and AQP2 in PKA knockout cell lines of the renal cortex collecting duct (mpkCCD cells). FMP-API-1 holds potential for studying nephrogenic diabetes insipidus (NDI).Formula:C13H14N2O2Color and Shape:SolidMolecular weight:230.262ES-072
CAS:ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.Formula:C25H27F3N8O2Color and Shape:SolidMolecular weight:528.53EGFR-IN-23
CAS:EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.Formula:C36H44BrN10O3PColor and Shape:SolidMolecular weight:775.68TrkC-IN-1
CAS:TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.Formula:C28H20BrN5O2Color and Shape:SolidMolecular weight:538.395c-Met-IN-2
CAS:c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.Formula:C24H21FN10OPurity:98%Color and Shape:SolidMolecular weight:484.49EGFR/HER2-IN-7
EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.Formula:C19H21N3O2SColor and Shape:SolidMolecular weight:355.45D-69491 hydrochloride
CAS:D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.Formula:C25H26Cl2FN7O3Color and Shape:SolidMolecular weight:562.42EGFR-IN-132
CAS:EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.Formula:C27H31N7O3Color and Shape:SolidMolecular weight:501.58Tesevatinib tosylate
CAS:Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Formula:C31H33Cl2FN4O5SColor and Shape:SolidMolecular weight:663.59BNN-20
CAS:BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.Formula:C20H30O2Color and Shape:SolidMolecular weight:302.45EGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formula:C27H19ClFN3OColor and Shape:SolidMolecular weight:455.91Ligritinib
CAS:Ligritinib (AB801) is an orally active inhibitor of the AXL receptor tyrosine kinase. By inhibiting the kinase activity of AXL, Ligritinib blocks its downstream signaling pathways. It is utilized in cancer research, particularly in studies involving non-small cell lung cancer (NSCLC) in combination with chemotherapy.Formula:C33H32N6OColor and Shape:SolidMolecular weight:528.65N-Deshydroxyethyl Dasatinib-C3-NH2
CAS:N-Deshydroxyethyl Dasatinib-C3-NH2 is a target protein ligand-linker conjugate, comprising an LCK ligand and a PROTAC linker, designed to recruit E3 ligase. It is utilized in the synthesis of [PROTACSJ11646].Formula:C23H29ClN8OSColor and Shape:SolidMolecular weight:501.05DDR1/2 inhibitor-3
CAS:DDR1/2 inhibitor-3 (5n) is an inhibitor of DDR1/2, with IC50 values of 9.4 nM and 20.4 nM, respectively. It is applicable in anti-inflammatory research.Formula:C31H31F3N6OColor and Shape:SolidMolecular weight:560.613JBJ-09-063
CAS:JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formula:C31H29FN4O3SColor and Shape:SolidMolecular weight:556.65EGFR-IN-135
EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.Formula:C12H14N4OS2Color and Shape:SolidMolecular weight:294.4EGFR Ligand-Linker Conjugates 1
CAS:EGFRLigand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate comprising an EGFR ligand and a PROTAC linker, designed to recruit the E3 ligase. It is used in the synthesis of PROTACEGFRdegrader 3.Formula:C37H47N9O3Color and Shape:SolidMolecular weight:665.83PROTAC Her3-binding moiety 2
CAS:PROTACHer3-binding moiety 2 is an inhibitor of Her3. It is applicable in the synthesis of PROTACHer3 Degrader-8.Formula:C25H25N7O2Color and Shape:SolidMolecular weight:455.51EGFR-IN-130
EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.Formula:C27H25N3O6SColor and Shape:SolidMolecular weight:519.57EGFR/HER2/DHFR-IN-1
Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.Formula:C14H11BrN4O2SColor and Shape:SolidMolecular weight:379.23TrkA-IN-7
CAS:<p>TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.</p>Formula:C16H13N3O3Color and Shape:SolidMolecular weight:295.293JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formula:C27H20N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.54GENZ-882706
CAS:<p>GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor.</p>Formula:C26H25N5O3Purity:98%Color and Shape:SolidMolecular weight:455.51EGFR/HER2-IN-8
EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.Formula:C16H16N4O2SColor and Shape:SolidMolecular weight:328.39Juvenile hormone B 3 (mixture of diastereomers)
CAS:Juvenile hormone B 3 (Juvenile hormone III bisepoxide) (mixture of diastereomers) is a sesquiterpenoid hormone. It can be isolated from the corpora allata (CA) of higher dipteran insects such as fruit flies and Drosophila melanogaster. This hormone exhibits anti-metamorphic activity and induces the expression of Kr-h1 by directly interacting with juvenile hormone (JH) receptors (Met and Gce). Juvenile hormone B 3 (mixture of diastereomers) is applicable in insect lethality studies.Formula:C16H26O4Color and Shape:SolidMolecular weight:282.38HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Color and Shape:SolidMolecular weight:549.53EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formula:C21H23N3O5Color and Shape:SolidMolecular weight:397.424EGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Formula:C25H24ClN7O2Color and Shape:SolidMolecular weight:489.96EGFR-IN-125
CAS:EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).Formula:C30H26N8OColor and Shape:SolidMolecular weight:514.58AZ8010
CAS:AZ8010 (AZ12908010) serves as an effective inhibitor of FGFR1-3 and exhibits antiproliferative properties, making it useful for cancer research.Formula:C27H34N4O3Color and Shape:SolidMolecular weight:462.58EGFR-IN-58
EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.Formula:C31H30FN7OColor and Shape:SolidMolecular weight:535.61HER2-IN-7
CAS:HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.Formula:C28H26F3N7O3Color and Shape:SolidMolecular weight:565.55KRC-00715
CAS:KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.Formula:C25H25F3N8O3Color and Shape:SolidMolecular weight:542.51ROS1-IN-2
CAS:ROS1-IN-2 (Compound 3), a ROS1 inhibitor, is utilized in cancer research.Formula:C29H37ClN5O2PColor and Shape:SolidMolecular weight:554.06PF-06273340
CAS:PF-06273340 是一种口服具有活力的、具有选择性的外周限制性Trk 泛抑制剂。Formula:C23H22ClN7O3Purity:98% - 98.00%Color and Shape:SolidMolecular weight:479.92TRK-IN-28
CAS:TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].Formula:C27H25F2N7Color and Shape:SolidMolecular weight:485.53Tyrosine Protein Kinase Substrate
CAS:Tyrosine Protein Kinase Substrate is a polypeptide molecule with the sequence RRLIEDNEYTARG.Formula:C66H109N23O23Molecular weight:1592.71TRK-IN-26
CAS:TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].Formula:C30H22F2N6O4Color and Shape:SolidMolecular weight:568.53DDR1-IN-8
CAS:DDR1-IN-8 (compound 7s) is a potent inhibitor of DDR1/2, exhibiting IC50 values of 0.045 μM and 0.126 μM, respectively, and possesses antitumor activity.Formula:C23H24F3N5O2Molecular weight:459.46DYR530
CAS:DYR530 is a ligand for the target protein (protein kinase DYRK1A) of PROTAC.Formula:C23H24FN7Color and Shape:SolidMolecular weight:417.48Enrupatinib
CAS:Enrupatinib is an inhibitor of the colony stimulating factor 1 receptor (CSF1R), exhibiting antitumor activity.Formula:C27H26N6O3Color and Shape:SolidMolecular weight:482.53c-Fms-IN-15
CAS:c-Fms-IN-15 (compound 8g) is a potent inhibitor of FMS kinase, with an IC50 of 563 nM.Formula:C29H28F3N7O2Molecular weight:563.57c-Met-IN-26
CAS:c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.Formula:C24H19F2N9Color and Shape:SolidMolecular weight:471.46Fanregratinib
CAS:Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.Formula:C27H33ClN6O2Color and Shape:SolidMolecular weight:509.04Protein kinase inhibitor 4
CAS:Protein kinase inhibitor 4 (Compound 3) is a chemical that acts as a protein kinase inhibitor, specifically targeting TRK-A with an IC50 of 3.0 nM, and ROS1 with an IC50 of 104 nM.Formula:C25H24F2N6O3SMolecular weight:526.56MerTK-IN-1
CAS:MerTK-IN-1 (compound 31) serves as an inhibitor of MerTK, with the capability to bind to the target in vivo.Formula:C23H26N8O4Color and Shape:SolidMolecular weight:478.50EGFR-IN-149
CAS:EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.Formula:C16H15N3OSColor and Shape:SolidMolecular weight:297.375Dyrk1A-IN-11
CAS:Dyrk1A-IN-11 (compound 166) is an effective inhibitor targeting dual-specificity tyrosine phosphorylation-regulated 1A (DYRK1A) with an EC50 of 0.0021 µM. Additionally, this compound inhibits the phosphorylation of Tau (Thr212) with an EC50 of 0.0361 µM.Formula:C23H23F5N8OColor and Shape:SolidMolecular weight:522.47c-Kit-IN-8
CAS:C-Kit-IN-8 (Compound 53) acts as an inhibitor of c-Kit kinase, hampering uKIT kinase activity with an IC50 greater than 1 μM. Additionally, it inhibits the proliferation of both wild-type and mutant GIST430 and BaF3 cancer cells, exhibiting an IC50 greater than 0.1 μM.Formula:C24H26FN5O4Color and Shape:SolidMolecular weight:467.49EGFR-IN-18
EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).Formula:C33H28N6O3SColor and Shape:SolidMolecular weight:588.68EGFR-IN-17
EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.Formula:C27H31ClN7O3PColor and Shape:SolidMolecular weight:568.01EGFR-IN-24
EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).Formula:C30H35FN6O3Color and Shape:SolidMolecular weight:546.64PET-cGMP
CAS:<p>PET-cGMP is an analogue of cyclic guanosine monophosphate and functions as a potent, selective agonist for PKGI. It exhibits an EC50 of 3.8 nM for PKGIβ and 193 nM for PKGII.</p>Formula:C18H16N5O7PColor and Shape:SolidMolecular weight:445.323NSC381467
CAS:NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.Formula:C20H16O7Color and Shape:SolidMolecular weight:368.34DDR1-IN-10
CAS:DDR1-IN-10 (compound 7q) is an inhibitor of DDR1. It is applicable in research related to pancreatic cancer, non-small cell lung cancer, and gastric cancer.Formula:C24H25F4N5O2Color and Shape:SolidMolecular weight:491.481AMG-25
CAS:AMG-25 (c-Kit-IN-5-1) is a c-Kit inhibitor that inhibits c-Kit, KDR, p38, Lck, and Src, and can be used for the study of mast cell-associated fibrotic diseases.Formula:C23H17N5O2Purity:98.16%Color and Shape:SolidMolecular weight:395.41HER2-IN-6
CAS:HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)Formula:C26H32N8O3Color and Shape:SolidMolecular weight:504.58EGFR-IN-139
CAS:EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).Formula:C27H25ClN2O4Color and Shape:SolidMolecular weight:476.951EGFR-IN-34
EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.Formula:C26H27ClN6O2Color and Shape:SolidMolecular weight:490.98Sacibertinib
CAS:Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.Formula:C32H31ClN6O4Color and Shape:SolidMolecular weight:599.08SORT1-IN-5
CAS:SORT1-IN-5 (compound 3) is a SORT1 inhibitor capable of crossing the blood-brain barrier. The MSOH salt form of SORT1-IN-5 exhibits a certain degree of oral bioavailability.Formula:C19H31NO6SColor and Shape:SolidMolecular weight:401.52Si306
CAS:Si306, an Src inhibitor, exhibits antitumor activity by reducing the phosphorylation of focal adhesion kinase (FAK) and the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM).Formula:C25H26BrClN6OSColor and Shape:SolidMolecular weight:573.94MerTK/Axl-IN-1
CAS:MerTK/Axl-IN-1 (Compound A-910) is a potent and selective dual inhibitor of MerTK/Axl, exhibiting IC50 values of 4.2 nM and 8.8 nM in Ba/F3 cells, and 0.2 nM and 0.9 nM in HTRF cells, respectively. It effectively inhibits pMerTK in vivo and possesses a long half-life and high oral bioavailability.Formula:C40H47FN6O4Color and Shape:SolidMolecular weight:694.84Anticancer agent 109
CAS:Anticancer agent 109 (compound 6-15) acts as an inhibitor targeting the Gas6-Axl axis, demonstrating significant anti-cancer properties. This compound suppresses the expression of Gas6, Axl, p-PI3K, and p-AKT in cancer cells, thereby inducing G1 phase arrest and promoting apoptosis of cancer cells. Additionally, Anticancer agent 109 effectively inhibits tumor growth in nude mouse tumor-bearing models [1].Formula:C19H15N3O2Color and Shape:SolidMolecular weight:317.34MerTK-IN-3
CAS:MerTK-IN-3 (compound 11) is an orally active, selective inhibitor of MerTK, exhibiting IC50 values of 21.5 nM for MerTK and 991.3 nM for Tyro3. It is applicable in colon cancer research.Formula:C36H31FN8O4Color and Shape:SolidMolecular weight:658.68EGFR-IN-160
CAS:EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).Formula:C15H12N2O4Color and Shape:SolidMolecular weight:284.27DYRKs-IN-1
CAS:<p>DYRKs-IN-1 has antitumor activity.</p>Formula:C30H30ClN7O4Purity:98%Color and Shape:SolidMolecular weight:588.06TrkA-IN-8
CAS:TrkA-IN-8 (Compound 2) is a TrkA inhibitor with a Kd value of 3.3 µM. RTKs-IN-1 demonstrates a concentration-dependent inhibitory effect on the proliferation of lung cancer cell lines and holds potential for research in non-small cell lung cancer.Formula:C20H16N4Color and Shape:SolidMolecular weight:312.368EGFR-IN-126
CAS:EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.Formula:C28H28BrFN4O3Color and Shape:SolidMolecular weight:567.45IGF-1R inhibitor-4
CAS:IGF-1Rinhibitor-4 (compound 22) is a potent inhibitor of IGF-1R, demonstrating an inhibition rate of 63% at a concentration of 10 μM. This compound plays a significant role in cancer research.Formula:C13H15ClN4OColor and Shape:SolidMolecular weight:278.737HER2-IN-12
HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.Formula:C17H18BrN5O2SColor and Shape:SolidMolecular weight:436.33EG31
CAS:EG31 is an EGFR inhibitor that effectively suppresses the proliferation of triple-negative breast cancer (TNBC) cells by inhibiting the EGFR signaling pathway. It demonstrates a GI50 value of 498.90 nM for MDA-MB-231 cells and 740.73 nM for Hs578T cells, while also inducing apoptosis. Additionally, EG31 retains its antiproliferative activity against 5-fluorouracil (5-FU) resistant TNBC cells, with a GI50 of 519.5 nM. EG31 is applicable in research on TNBC resistance.Formula:C30H13Br2N3O6Color and Shape:SolidMolecular weight:671.25EGFR/HER2-IN-4
EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.Color and Shape:Solid8-Br-cGMP-AM
CAS:8-Br-cGMP-AM, a derivative of 8-Br-cGMP, acts as an activator of PKG (cGMP-dependent protein kinase), inducing various biological effects such as vasodilation and platelet inhibition. This compound is utilized in the research of cardiovascular diseases.Formula:C13H15BrN5O9PColor and Shape:SolidMolecular weight:496.16BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Formula:C18H15N3O2Color and Shape:SolidMolecular weight:305.331Andamertinib
CAS:Andamertinib is an EGFR inhibitor with antitumor activity.Formula:C31H36N8O3Color and Shape:SolidMolecular weight:568.669ITK inhibitor 2
CAS:ITK inhibitor 2 (compound 4) is a potent and selective ITK inhibitor with an IC50= 2 nM.Formula:C25H33N5O2Purity:99.67%Color and Shape:SolidMolecular weight:435.56HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Formula:C19H14BrF3N2OColor and Shape:SolidMolecular weight:423.23EGFR/BRAF-IN-1
EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.Formula:C26H28ClN3O4Color and Shape:SolidMolecular weight:481.97Tarloxotinib bromide
CAS:Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.Formula:C24H24Br2ClN9O3Purity:99.52%Color and Shape:SolidMolecular weight:681.77Ref: TM-T13088
1mg140.00€5mg283.00€10mg432.00€25mg707.00€50mg938.00€100mg1,311.00€1mL*10mM (DMSO)437.00€AZ12601011
CAS:AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.Formula:C19H15N5Purity:98.81%Color and Shape:SolidMolecular weight:313.36Ref: TM-T10426
1mg99.00€5mg235.00€10mg376.00€25mg728.00€50mg1,093.00€100mg1,510.00€1mL*10mM (DMSO)259.00€Zotizalkib
CAS:TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.Formula:C21H20F3N5O3Purity:98.7%Color and Shape:SolidMolecular weight:447.41Ref: TM-T9414
1mg120.00€5mg283.00€10mg464.00€25mg929.00€50mg1,473.00€100mg1,977.00€200mg2,802.00€1mL*10mM (DMSO)319.00€Enbezotinib
CAS:Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.Formula:C21H21FN6O3Purity:99.84%Color and Shape:SolidMolecular weight:424.43Ref: TM-T62285
1mg81.00€5mg170.00€10mg266.00€25mg437.00€50mg598.00€100mg787.00€1mL*10mM (DMSO)192.00€Vecabrutinib
CAS:<p>Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.</p>Formula:C22H24ClF4N7O2Purity:99.74%Color and Shape:SolidMolecular weight:529.92AGL-2263
CAS:AGL-2263 is a blocker of insulin receptor (IR)Formula:C17H10N2O5Color and Shape:SolidMolecular weight:322.27EGFR-IN-7
CAS:<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Formula:C32H41BrN9O2PPurity:95.32% - 99.64%Color and Shape:SolidMolecular weight:694.6Imbotolimod
Imbotolimod, a humanized monoclonal antibody of the immunoglobulin G1-kappa class, exhibits both anti-ERBB2 and antineoplastic activities.Color and Shape:Odour LiquidTyrosine kinase inhibitor
CAS:Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.Formula:C31H31FN6O5Purity:98%Color and Shape:SolidMolecular weight:586.61TLC9995-0188
CAS:Tyrosine-protein kinase ABL, IC50: 1500 nMFormula:C16H15N5Color and Shape:Yellow SolidMolecular weight:277.331Nimotuzumab (powder)
CAS:<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Color and Shape:LiquidHMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Color and Shape:Odour LiquidOlmutinib
CAS:Olmutinib (BI1482694) is a Novel Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorFormula:C26H26N6O2SPurity:99.14%Color and Shape:SolidMolecular weight:486.59Duligotuzumab
CAS:<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Purity:95%Color and Shape:LiquidRef: TM-T80604
Discontinued productEGFR-IN-82
CAS:<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Formula:C32H41BrN9O2PPurity:98%Color and Shape:SolidMolecular weight:694.6Trk-IN-4
CAS:Trk-IN-4 (PF-6683324) is a potent pan-Trk inhibitor and antinociceptive. It is also a selective type II PTK6 inhibitor antitumor.Formula:C24H23F4N5O4Purity:98.13%Color and Shape:SolidMolecular weight:521.46FGFR1 inhibitor-10
CAS:<p>FGFR1 inhibitor-10 (Compound 4i), with an IC50 of 28 nM, effectively inhibits FGFR1 phosphorylation.</p>Formula:C26H30F3N7O2SPurity:98%Color and Shape:SolidMolecular weight:561.62TrkB-IN-1
CAS:<p>TrkB-IN-1 is a potent, orally active agonist of the TrkB receptor, with favorable pharmacokinetic (PK) properties.</p>Formula:C19H16N2O6Purity:98%Color and Shape:SolidMolecular weight:368.34APG-2449
CAS:<p>APG-2449 is an orally active inhibitor targeting ALK, ROS1, and FAK, demonstrating antitumor efficacy in mouse models of non-small cell lung cancer (NSCLC) [1].</p>Formula:C33H42ClN5O4SPurity:98%Color and Shape:SolidMolecular weight:640.24Canlitinib
CAS:<p>Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.</p>Formula:C33H31F2N3O7Purity:98%Color and Shape:SolidMolecular weight:619.61YK-029A
CAS:<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Formula:C27H32N8O2Purity:98%Color and Shape:SolidMolecular weight:500.6BTK-IN-27
CAS:<p>BTK-IN-27 (example 8), a potent BTK inhibitor with an IC50 of 0.2 nM, demonstrates anti-proliferative effects in TMD8 cells with an IC50 of less than 5 nM.</p>Formula:C31H35N7O2Purity:98%Color and Shape:SolidMolecular weight:537.66JDB175
CAS:<p>JDB175, a selective BTK inhibitor with oral bioavailability, demonstrates excellent penetration through the blood-brain barrier.</p>Formula:C26H21F3N4O2Purity:98%Color and Shape:SolidMolecular weight:478.47Syk-IN-8
CAS:<p>Syk-IN-8 (compound 19q) functions as a Syk inhibitor with demonstrated antiproliferative effects on a variety of hematological tumor cells.</p>Formula:C23H26N10Purity:98%Color and Shape:SolidMolecular weight:442.52BTK-IN-25
CAS:<p>BTK-IN-25 (compound 71) is a potent BTK inhibitor, demonstrating an IC50 of 0.77 nM against BTK(C481S) and achieving an IC50 of 1 nM in DOHH2 cells [1].</p>Formula:C28H27F2N3O5Purity:98%Color and Shape:SolidMolecular weight:523.53EGFR-IN-122
CAS:<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Formula:C19H20N4O3Color and Shape:SolidMolecular weight:352.39Ref: TM-T200157
Discontinued productEGFR-IN-123
CAS:<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Formula:C24H27F3N6OColor and Shape:SolidMolecular weight:472.51Ref: TM-T200485
Discontinued product
